Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov 13;51(21):6650-3.
doi: 10.1021/jm800979v. Epub 2008 Oct 8.

Improved synthesis of 6-epi-dictyostatin and antitumor efficacy in mice bearing MDA-MB231 human breast cancer xenografts

Julie L Eiseman  1 , Lihua Bai, Won-Hyuk Jung, Gustavo Moura-Letts, Billy W Day, Dennis P Curran
Affiliations

Improved synthesis of 6-epi-dictyostatin and antitumor efficacy in mice bearing MDA-MB231 human breast cancer xenografts

Julie L Eiseman et al. J Med Chem. .

Abstract

Structure-activity studies centered on the naturally occurring antitumor agent dictyostatin have recently identified several highly active epimers and analogues. From these compounds, 6- epi-dictyostatin was selected for scaleup preparation and evaluation in animals. Here we describe a new total synthesis that produced more than 30 mg of 6- epi-dictyostatin. The compound was found to have potent antitumor activity in SCID mice bearing MDA-MB231 human breast cancer xenografts.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Retrosynthetic analysis of 6-epi-dictyostatin
Figure 2
Figure 2
Antitumor activity in MDA-MB231 human breast cancer xenograft-bearing C.B-17 SCID female mice (n = 10 animals per group) treated with 20 mg/kg iv q7dx3 6-epi-dictyostatin 1 (○) or paclitaxel (△), vehicle (▲), or no treatment (▽). Arrows inidicate the days of dosing.
Figure 3
Figure 3
Body weight changes in MDA-MB231 human breast cancer xenograft-bearing C.B.-17 SCID female mice (n = 10 animals per group) over the course of treatment with 20 mg/kg iv q7dx3 6-epi-dictyostatin 1 (○) or paclitaxel (△), vehicle (▲), or no treatment (▽). Arrows inidicate the days of dosing.
Scheme 1
Scheme 1
Fragment couplings and macrolactonization
See this image and copyright information in PMC

References

    1. Mooberry SL. Strategies for the development of novel Taxol-like agents. Methods Mol Med. 2007;137:289–302. - PubMed
    1. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother. Pharmacol. 2008 published online 2008 Mar 18 [PMID: 18347795] - PubMed
    1. Florence GJ, Gardner NM, Paterson I. Development of practical syntheses of the marine anticancer agents discodermolide and dictyostatin. Nat. Prod. Rep. 2008;25:342–375. - PubMed
    1. Pettit GR, Cichacz ZA, Gao F, Boyd MR, Schmidt JM. Isolation and structure of the cancer cell growth inhibitor dictyostatin 1. J. Chem. Soc. Chem. Comm. 1994:1111–1112.
    1. Isbrucker RA, Cummins J, Pomponi SA, Longley RA, Wright AE. Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. Biochem. Pharmacol. 2003;66:75–82. - PubMed

Publication types